Home>Topics>Stocks>Exact Sciences

Exact Sciences EXAS

  1. All
  2. Commentary
  3. Headlines
    1. Mayo Clinic signs on with Cologuard

      Headlines

      Mon, 25 Aug 2014

      The Mayo Clinic will offer Exact Sciences ' ( EXAS +4.8% ) Cologuard as a screen for colorectal cancer. The test will be available to patients through their primary care physicians. It is the first health system to sign on to offer the test. Post your comment!

    2. Update: Exact Sciences' Cologuard Has Been Approved By FDA

      Headlines

      Fri, 15 Aug 2014

      By Andy Batts : Exact Sciences (NASDAQ: EXAS ) has bagged FDA approval for ..... colorectal cancer. Upon approval, Exact Sciences instantly received a proposed ..... healthcare providers for $599. Exact Sciences CEO Kevin Conroy told FierceMedicalDevices

    3. Premarket Gainers / Losers

      Headlines

      Tue, 12 Aug 2014

      Gainers: ICPT +45% . FRF +40% . INSY +15% . SUPN +14% . EXAS +8% . CNAT +8% . ARTX +6% . Losers: DNDN -23% . GALE -12% . CALL -10% . NUAN -9% . TKMR -8% . FLO -8% . HCLP -5% . Post your comment!

    4. BRIEF-MDxHealth says US FDA approves colorectal cancer test using its biomarkers

      Headlines

      Tue, 12 Aug 2014

      * U.S. Food and Drug Administration has approved Exact Sciences ' cologuard stool-DNA-based, non-invasive colorectal cancer screening test

    5. FDA approves Exact Sciences' colorectal screening test

      Headlines

      Mon, 11 Aug 2014

      The FDA clears Exact Sciences ' ( EXAS +2.5% ) Cologuard , a stool-based colorectal screening test ..... proposes to cover the cost of the test once every three years. EXAS shares are up 4% AH on average volume. Post your comment!

    6. 2nd Half Of 2014 Biotechnology Catalysts-Part 3

      Headlines

      Mon, 4 Aug 2014

      By Alexander Maxwell : It can be very hard for investors to be able to keep track of all of the different events going on within the biotech world, with clinical trial results, and FDA decisions happening rather frequently. The purpose of this article is to hopefully make investor's lives a little

    7. Amidst Ongoing Doubts, Exact Sciences Still Offers Opportunity

      Headlines

      Wed, 23 Jul 2014

      CFA : For a modestly-sized diagnostics stock, Exact Sciences (NASDAQ: EXAS ) seems to generate an above-average level of ..... and I continue to believe that is the case with Exact Sciences . My thesis in brief - the Cologuard works, is

    8. EXACT Sciences' ( EXAS ) CEO Kevin Conroy on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Tue, 22 Jul 2014

      EXACT Sciences Corporation (NASDAQ: EXAS ) Q2 2014 Earnings Conference Call July 22, 2014 10:00 AM ET Executives Rod Hise ..... Operator Good day, ladies and gentlemen, welcome to the Exact Sciences Second Quarter 2014 Earnings Conference Call. At this time

    9. More on Exact Sciences Q2 results

      Headlines

      Tue, 22 Jul 2014

      Exact Sciences (NASDAQ: EXAS ) Q2 results : Revenues: $0; R&D Expense: $7.2M (+11.1%); SG&A Expense: $12.4M (+78.9%); Operating

    10. Exact Sciences EPS in-line

      Headlines

      Tue, 22 Jul 2014

      Exact Sciences (NASDAQ: EXAS ): Q2 EPS of -$0.24 in-line. Press Release Post your comment!

    « Prev123Next »
    Content Partners